Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18492198 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20021228 | 0.93 | MAPT (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL18773764 | 0.79 | ALDH1A1 (0.42) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL11940662 | 0.76 | ACLY (0.48) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL31642268 | 0.76 | NAALAD2 (0.35) | CYP2D6CYP2C19ALDH1A1NAALAD2 | |
| SCHEMBL9256362 | 0.76 | CYP2D6 (0.43) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL23845802 | 0.75 | NAALAD2 (0.38) | NAALAD2 | |
| SCHEMBL7741623 | 0.73 | CES2 (0.41) | HSD17B10ALDH1A1 | |
| SCHEMBL601002 | 0.73 | ARG1 (0.52) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1921733 | 0.73 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| EP-3301108-A1 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | CYP1A2 2855/4885CYP2D6 4191/4885MAPT 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.